Patrick Smith Sells 10,000 Shares of Axon Enterprise (NASDAQ:AXON) Stock

Axon Enterprise, Inc (NASDAQ:AXON) CEO Patrick Smith sold 10,000 shares of the stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $500.24, for a total transaction of $5,002,400.00. Following the sale, the chief executive officer owned 3,090,997 shares in the company, valued at $1,546,240,339.28. The trade was a 0.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Axon Enterprise Trading Down 1.4%

Shares of AXON stock opened at $542.40 on Friday. Axon Enterprise, Inc has a fifty-two week low of $396.41 and a fifty-two week high of $885.91. The stock’s fifty day moving average price is $537.92 and its two-hundred day moving average price is $625.54. The company has a debt-to-equity ratio of 0.53, a quick ratio of 2.89 and a current ratio of 2.53. The company has a market cap of $43.61 billion, a PE ratio of 356.84, a P/E/G ratio of 16.57 and a beta of 1.48.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.55. The business had revenue of $796.72 million for the quarter, compared to analyst estimates of $755.29 million. Axon Enterprise had a return on equity of 2.82% and a net margin of 4.48%.Axon Enterprise’s revenue was up 38.5% compared to the same quarter last year. During the same period last year, the firm posted $2.08 earnings per share. Equities analysts predict that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Axon Enterprise News Summary

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q4 beat and bullish bookings — Axon reported a double beat (EPS and revenue), ~39% revenue growth and a material increase in future contracted bookings with raised multi‑year sales targets, which triggered the stock rally. Read More.
• Positive Sentiment: AI narrative driving subscription demand — Coverage highlights that Axon’s AI features (body‑camera analytics, Draft One report drafting, evidence management) are accelerating software adoption and upsells, supporting revenue visibility beyond hardware. Read More.
• Neutral Sentiment: Analysts recalibrating models — Several firms trimmed price targets after the print (Piper Sandler, others); many maintained buy/overweight stances, so these moves reflect model updates and volatility rather than a wholesale negative verdict. Read More.
• Neutral Sentiment: Short‑interest data flagged as anomalous — Recent short‑interest reports show zero/NaN figures (likely a reporting anomaly); nothing actionable from that data point for now.
• Negative Sentiment: Some analysts flag downside risk — Morgan Stanley and UBS issued more cautious outlooks/pessimistic scenarios that could cap upside if execution or margins slip. Read More. | Read More.
• Negative Sentiment: Profitability and margin recovery remain a watch item — Commentators note fast revenue growth but slower profit improvement and the need for FCF conversion; sustained margin progress is required to justify high multiples. Read More.
• Negative Sentiment: Insider sale disclosed — CEO Patrick Smith sold 10,000 shares (~$5.0M) on Feb. 25; small relative to his holdings but notable to traders monitoring insider activity. Read More.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on AXON. Royal Bank Of Canada cut their price objective on Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating on the stock in a report on Wednesday. Piper Sandler dropped their target price on Axon Enterprise from $753.00 to $690.00 and set an “overweight” rating for the company in a research report on Wednesday. Citigroup restated a “buy” rating on shares of Axon Enterprise in a report on Wednesday. William Blair reaffirmed an “outperform” rating on shares of Axon Enterprise in a research note on Tuesday, February 3rd. Finally, Morgan Stanley cut their target price on shares of Axon Enterprise from $713.00 to $675.00 and set an “overweight” rating on the stock in a research report on Wednesday. Sixteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $762.93.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Brighton Jones LLC bought a new stake in Axon Enterprise in the fourth quarter worth approximately $480,000. NewEdge Advisors LLC increased its stake in shares of Axon Enterprise by 41.1% in the 1st quarter. NewEdge Advisors LLC now owns 2,294 shares of the biotechnology company’s stock valued at $1,207,000 after acquiring an additional 668 shares in the last quarter. Empowered Funds LLC lifted its position in shares of Axon Enterprise by 8.4% during the 1st quarter. Empowered Funds LLC now owns 2,028 shares of the biotechnology company’s stock valued at $1,067,000 after acquiring an additional 157 shares during the period. Woodline Partners LP lifted its position in shares of Axon Enterprise by 40.6% during the 1st quarter. Woodline Partners LP now owns 6,932 shares of the biotechnology company’s stock valued at $3,646,000 after acquiring an additional 2,003 shares during the period. Finally, Sivia Capital Partners LLC bought a new position in Axon Enterprise during the second quarter worth $284,000. Institutional investors own 79.08% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.